BCRX

AI Memo

BioCryst

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

November 4 results: ORLADEYO uptake and guidance • 2026-11-04

Base target: $9 / p=45% prob

Biggest risk

Pediatric prescriptions may convert slowly, emerging oral competition may constrain growth, and early BCX17725 or later navenibart data may disappoint. Second-quarter total revenue included $55.7 million recognized from a licensing agreement, so it should not be treated as recurring ORLADEYO demand. [#8-K-2026-08-05] BioCryst earnings exhibit

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Sustained ORLADEYO uptake and a successful pediatric launch could support guidance while pipeline readouts add optionality. BioCryst maintained 2026 ORLADEYO guidance and reported positive second-quarter operating profit. [#8-K-2026-08-05] BioCryst earnings exhibit

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

p=45%

Bull target

$12

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Navenibart ALPHA-ORBIT readout
Sustained ORLADEYO uptake and a successful pediatric launch could support guidance while pipeline readouts add optionality.
BioCryst maintained 2026 ORLADEYO guidance and reported positive second-quarter operating profit.

BearKey bullets

BCX17725's small Phase 1 dataset and the later navenibart pivotal readout carry clinical and timing risk.
BioCryst earnings exhibit
Licensing revenue boosted second-quarter total revenue; recurring product demand and cash generation require separate monitoring.

WatchKey bullets

November 4 results: ORLADEYO uptake and guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +41% / -41%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $9 (p=45%)Bear Target: $5 (p=30%)

Commentary

The deterministic prior is positive, but low coverage, prospective competition and limited verified analyst-revision data favor monitoring rather than a strong bullish call. The $7.65 October 23 anchor is about 1.8% below the prior baseline's $7.79 October 16 anchor; no cause for that interval move was established. The September negative headlines are secondary context, not proof of operating deterioration. Social, options, short-interest and employee-sentiment figures are unavailable; the zero entries are missing-data placeholders, not measured readings.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Navenibart ALPHA-ORBIT readout

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-04
November 4 results: ORLADEYO uptake and guidance
BioCryst has scheduled third-quarter results for November 4. The decision point is whether ORLADEYO sales, including the pediatric oral-pellet launch, support its maintained $625 million–$645 million 2026 product-revenue guidance. Second-quarter ORLADEYO revenue was $158.2 million; early pediatric prescriptions are not yet proof of sustained paid uptake. [#PR-EARNINGS-2026-10-21] [#8-K-2026-08-05] BioCryst earnings exhibit
Prob 60.00% • Move 8.00% • Priced-in 50.00%
EVENT2026-12-31
BCX17725 early patient data
BioCryst expects data by year-end from a Phase 1 Netherton syndrome study segment enrolling up to 12 patients for three months. The small, early-stage dataset may be difficult to interpret. [#8-K-2026-08-05] BioCryst earnings exhibit
Prob 60.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Navenibart ALPHA-ORBIT readout
2027-09-30
Enrollment is complete, and BioCryst targets third-quarter 2027 top-line results for every-three-month and every-six-month dosing in hereditary angioedema. Clinical differentiation remains unproven. [#8-K-2026-08-05] BioCryst earnings exhibit
Prob 75% • Move 18% • Priced-in 30%

Risks

BCX17725's small Phase 1 dataset and the later navenibart pivotal readout carry clinical and timing risk. BioCryst earnings exhibit
Licensing revenue boosted second-quarter total revenue; recurring product demand and cash generation require separate monitoring. BioCryst earnings exhibit
ORLADEYO pediatric prescription-to-paid-patient conversion and the transition to a sole-source specialty pharmacy may fall short of expectations. BioCryst earnings exhibit
Pharvaris's positive Phase 3 oral prophylaxis results create prospective hereditary-angioedema competition; cross-trial comparisons cannot establish relative efficacy. Pharvaris release

Peers

Symbol	Summary
TAK	Treatment-market comparator through TAKHZYRO hereditary-angioedema prophylaxis, but Takeda's diversified business makes it a loose corporate valuation peer. Takeda release
PHVS	Direct oral hereditary-angioedema development comparator. Pharvaris reported positive Phase 3 prophylaxis results in September 2026, raising prospective competition; its investigational therapy has not been compared head-to-head with ORLADEYO. Pharvaris release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

TAK

Treatment-market comparator through TAKHZYRO hereditary-angioedema prophylaxis, but Takeda's diversified business makes it a loose corporate valuation peer. Takeda release

PHVS

Direct oral hereditary-angioedema development comparator. Pharvaris reported positive Phase 3 prophylaxis results in September 2026, raising prospective competition; its investigational therapy has not been compared head-to-head with ORLADEYO. Pharvaris release